A New Anti-Diabetes Drug as a Novel Therapy for Ovarian Cancer

Project: Research

Status	Finished
Effective start/end date	1/01/16 → 31/12/20

DPP4 inhibitor sitagliptin enhances lymphocyte recruitment and prolongs survival in a syngeneic ovarian cancer mouse model
Wilson, A. L., Moffitt, L. R., Wilson, K. L., Bilandzic, M., Wright, M. D., Gorrell, M. D., Oehler, M. K., Plebanski, M. & Stephens, A. N., 1 Feb 2021, In: Cancers. 13, 3, p. 1-18 18 p., 487.
Research output: Contribution to journal › Article › Research › peer-review

Open Access

22 Citations (Scopus)
Non-invasive fluorescent monitoring of ovarian cancer in an immunocompetent mouse model
Wilson, A. L., Wilson, K. L., Bilandzic, M., Moffitt, L. R., Makanji, M., Gorrell, M. D., Oehler, M. K., Rainczuk, A., Stephens, A. N. & Plebanski, M., 1 Jan 2019, In: Cancers. 11, 1, 19 p., 32.
Research output: Contribution to journal › Article › Research › peer-review

Open Access
File

16 Citations (Scopus)
Autoantibodies against HSF1 and CCDC155 as biomarkers of early-Stage, high-Grade serous ovarian cancer
Wilson, A. L., Moffitt, L. R., Duffield, N., Rainczuk, A., Jobling, T. W., Plebanski, M. & Stephens, A. N., 1 Feb 2018, In: Cancer Epidemiology, Biomarkers and Prevention. 27, 2, p. 183-192 10 p.
Research output: Contribution to journal › Article › Research › peer-review

23 Citations (Scopus)

Project Details